Evaluation of son-1010 using a patient-derived tumoroid platform to support an ongoing phase 1 study in patients with sarcoma

Houston, oct. 15, 2025 (globe newswire) -- sonnet biotherapeutics holdings, inc. (nasdaq:sonn) is collaborating with spanios on a non-clinical study using new alternate methodologies (nam)-based patient-derived tumoroid (pdt) platforms that emulate the tumor microenvironment (tme) ex vivo to evaluate the effect of son-1010 (il-12-fhab) in soft tissue sarcoma. the study aims to speed up the development of treatments for patients with rare and difficult-to-treat cancers.
SONN Ratings Summary
SONN Quant Ranking